Literature DB >> 8482842

A functional analysis of the antigenicity of streptokinase using monoclonal antibody mapping and recombinant streptokinase fragments.

G L Reed1, P Kussie, B Parhami-Seren.   

Abstract

Streptokinase (SK), a bacterial product of pathogenic Streptococcus species, is now widely used as an effective therapy for the treatment of heart attacks. Because naturally occurring antibody to SK is ubiquitous, serious allergic reactions to SK therapy are common. To begin to identify regions of the molecule that are important for the antigenicity of SK we performed studies using a panel of 51 hybridomas producing anti-SK antibodies, recombinant SK fragments, and assays of SK activity. Antibodies generated from mice hyperimmunized with wild-type SK were shown to fall into six distinct complementation groups by competitive binding studies. Recombinant SK fragments were used to determine the peptide regions recognized by these complementation groups. Correlation of the effects of the mAb on SK function, with knowledge of their SK fragment-binding pattern, suggested regions of the SK molecule that are important for the construction and the catalytic function of the SK-plasminogen activator complex.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482842

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

Review 1.  Streptokinase--the drug of choice for thrombolytic therapy.

Authors:  Adinarayana Kunamneni; Thaer Taleb Abed Abdelghani; Poluri Ellaiah
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

2.  Mapping of the plasminogen binding site of streptokinase with short synthetic peptides.

Authors:  D Nihalani; G P Raghava; G Sahni
Journal:  Protein Sci       Date:  1997-06       Impact factor: 6.725

3.  Design of a DNA-Programmed Plasminogen Activator.

Authors:  Purba Mukherjee; Luke J Leman; John H Griffin; M Reza Ghadiri
Journal:  J Am Chem Soc       Date:  2018-11-01       Impact factor: 15.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.